Clene

Clene Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Clene (CLNN) as of Nov 16, 2026 is -7,257.56. In the previous year, Cash Conversion Cycle (CCC) was -6,042.84 — a change of 20.10% (lower).

Cash Conversion Cycle

-7,257.56

YoY

20.10%

Last updated:

Cash Conversion Cycle (CCC) of Clene is 2025 -7,257.56 . Cash Conversion Cycle (CCC) of Clene was 2024 -6,042.84 . It decreases by 20.10% lower compared to the previous year.

The Clene Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-349.18 USD
Jan 1, 2020
-5,203.72 USD
Jan 1, 2021
-2,351.68 USD
Jan 1, 2022
-41,561.65 USD
Jan 1, 2023
-4,345.44 USD
Jan 1, 2024
-6,042.84 USD
Jan 1, 2025
-7,257.56 USD
The Clene Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-7,257.56+20.10%
-6,042.84+39.06%
-4,345.44-89.54%
-41,561.65+1,667.32%
-2,351.68-54.81%
-5,203.72+1,390.25%
-349.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Cash Conversion Cycle (CCC) of Clene is -7,257.56 in 2025.

Cash Conversion Cycle (CCC) of Clene changed from -6,042.84 to -7,257.56, representing a 20.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Clene since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clene

All Key Metrics — Clene